Relationship between immunosuppression and intensive care unit-acquired multidrug-resistant bacteria: a case-control study

Crit Care Med. 2007 May;35(5):1318-23. doi: 10.1097/01.CCM.0000261885.50604.20.

Abstract

Objective: To determine the relationship between immunosuppression and intensive care unit (ICU)-acquired multidrug-resistant (MDR) bacteria.

Design: Retrospective case-control study based on prospectively collected data.

Setting: A 30-bed medical and surgical ICU.

Patients: All patients hospitalized >48 hrs in the ICU were eligible during a 2-yr period.

Interventions: Immunosuppression was defined as active solid or hematologic malignancy, leucopenia, or chronic immunosuppressive treatment. MDR bacteria were defined as methicillin-resistant Staphylococcus aureus, ceftazidime- or imipenem-resistant Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, and extending spectrum beta-lactamase producing Gram-negative bacilli. MDR bacteria screening (nasal, anal, and axilla swabs and tracheal aspirate in intubated patients) was performed at ICU admission and weekly. Only MDR bacteria isolated >48 hrs after ICU admission were taken into account; duplicates were excluded. Isolation measures were applied in all patients at ICU admission, in patients with MDR bacteria, and in patients with immunosuppression. Immunosuppressed patients (cases) were matched (1:1) with immunocompetent patients (controls) according to all the following criteria: age +/-5 yrs, Simplified Acute Physiology Score II +/-5, duration of ICU stay +/-3 days, and category of admission (medical/surgical). Risk factors for ICU-acquired MDR bacteria were determined using univariate and multivariate analyses.

Measurements and main results: Of 1,065 eligible patients, nine patients were excluded for absence of MDR bacteria screening at ICU admission. One hundred thirty-three (12%) patients were immunosuppressed, and 128 (96%) of them were successfully matched. Mean time between ICU admission and first ICU-acquired MDR bacteria was 12 +/- 9 days. Incidence of MDR bacteria was significantly higher in cases than in controls (22 vs. 12 MDR bacteria/1000 ICU days, p = .004). However, immunosuppression was not independently associated with ICU-acquired MDR bacteria.Multivariate analysis identified prior antibiotic treatment and antibiotic treatment in the ICU as risk factors for ICU-acquired MDR bacteria (odds ratio [95% confidence interval] = 1.9 [1-3.6], p = .003; 11 [1.4-83], p = .02; respectively).

Conclusions: Immunosuppression is not independently associated with ICU-acquired MDR bacteria. However, infection control measures used in our ICU may have influenced this result.

MeSH terms

  • Anti-Bacterial Agents / adverse effects*
  • Bacterial Infections / etiology*
  • Case-Control Studies
  • Cross Infection / etiology*
  • Cross Infection / microbiology
  • Drug Resistance, Multiple, Bacterial*
  • Female
  • Humans
  • Immunosuppression Therapy / adverse effects*
  • Infection Control
  • Intensive Care Units*
  • Length of Stay
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neoplasms / complications
  • Respiration, Artificial / adverse effects
  • Retrospective Studies
  • Risk Factors

Substances

  • Anti-Bacterial Agents